Clinical trial · Interventional
Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells
Effect of Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells : a Randomized Double Blind Placebo-controlled Trial
NCT03618472CI-TRIAL-00083216completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CA Endometrium | — | UNRESOLVED | — |
| Metformin | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin Hydrochloride 850 MG | Drug | Metformin | ALIAS |
| Placebo Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- metformin
- description
- The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
- interventionNames
- Drug: Metformin Hydrochloride 850 MG
- type
- PLACEBO_COMPARATOR
- label
- placebo
- description
- The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
- interventionNames
- Drug: Placebo Oral Tablet
Primary outcomes (1)
- measure
- Change of Ki-67 expression in endometrial tumor
- timeFrame
- 4 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Women with endometrial cancer who undergoing complete surgical staging and agrees to participate in this study Exclusion Criteria: * Women without diabetes type 1 and 2 * Women who have allergy Biguanide * Women who have hypoglycemic medication * Women who have GFR \<45 ml/min/1.73 m2 * Women who have evidence of stage 3 or 4 of endometrial cancer
References
Publications (0)
Data not yet available
No reference posted for this study.